Advertisement

Webinars

Different HTA Perspectives on Reliably Estimating Treatment Effects

October 31st, 2022|

Real-World evidence (RWE) has recently received increased attention to provide supplementary evidence to support health technology assessment (HTA) submissions, especially as another source of insight into the real-world performance of novel therapeutic products, particularly when traditional randomized controlled trials (RCTs) are impractical or lack generalizability. This webinar will focus on understanding how different HTA bodies view the use of RWE to estimate comparative treatment effects for HTA submissions. A case-study using RWE identified through an ongoing International Society for Pharmacoepidemiology (ISPE) funded project will be presented to the representatives of different HTA bodies to understand how they might evaluate the credibility of such evidence in the context of the HTA process with emphasis on issues around data quality and methodological rigor. An interactive discussion between the presenters will provide an opportunity to discuss trade-offs between data availability, quality and applicability of RWE use in HTA submissions, along with challenges in the interpretation of such evidence for healthcare decision making.

ISPOR Europe, Middle East and Africa Health Policy Update Meeting

October 31st, 2022|

Hosted by ISPOR Central and Eastern Europe Consortium, ISPOR Africa Network and ISPOR Arabic Network, this virtual meeting will present timely health policy and health economics and outcomes research (HEOR) updates from key experts in the Europe, Middle East, and Africa (EMEA) region. Presentations will be followed with an opportunity for Q&A. Meeting to be held virtually via Zoom.

Champion a seamless end-to-end insight generation process

October 31st, 2022|

Insights are the foundation to make smarter, data-driven, customer-centric business decisions that accelerate growth commercial success and build your commercial powerhouse. But there are still gaps in the way we handle the end-to-end insight processes: from capturing the insights that field forces generate to processing data and forming easy-to-action analytics; and from closing insight loops to meeting customer needs.

Social Media Data: Opportunities and Insights for Clinical Research

October 25th, 2022|Categories: , |Tags: , |

Hear four experts from ICON and Kap Code provide insights on how to collect, use, analyze, and interpret social media data in different contexts. These experts share knowledge from over fifteen years of successfully developing and adapting algorithms to treat this kind of data.

Workshop: Harnessing the Power of EHR Data and AI to Advance Biomedical Research

October 4th, 2022|

At this workshop, hosted by Penn State's Clinical and Translational Science Institute (CTSI) and Institute for Computational and Data Sciences (ICDS), three research groups from the College of Medicine will discuss why and how they have applied AI methods in their research. Attendees will also learn about the resources available to all Penn State researchers through CTSI and ICDS, which include access to anonymized electronic health records data, cloud-based analysis tools, and a computational consulting team that supports data science and AI throughout the University.

Health Insurance in Africa: Sustainability in Focus

October 4th, 2022|

Many health systems in Africa are generally characterized by high burden of out-of-pocket payment by patients at the point of care and increased exposure of clients to catastrophic health payments. However, there are recent moves by many African countries to improve their health financing systems and institute health insurance in a bid to ensure universal health coverage. The webinar will focus on sharing experiences of implementing health insurance in the contexts of African countries. As such, the main learning objectives of the webinar are to share best practices from countries, which are at different stages of implementing health insurance and identify mitigating strategies for the challenges that may be faced in the process of implementing health insurance.

The Biotech landscape: Market trends, priorities, predictions, and pathways to FDA approval

September 27th, 2022|Categories: , , |Tags: , , |

As we adjust to the post-COVID environment, hear from industry leaders about the biotech global investment and drug pipeline environment. In addition, we'll look at why biotech companies are increasingly exploring clinical opportunities in APAC, to achieve FDA accepted data and what actionable strategies can be implemented to leverage APAC's streamlined regulatory processes and accelerated clinical development. Our Regulatory affairs leaders from North America and Australia will share insight into processes supporting a robust clinical program, and how Phase 1 FDA accepted data from Australia, specifically, can launch global drug development programs.

Fit for Local Context? Establishing or Improving Deliberative Processes for HTA

September 19th, 2022|Categories: |Tags: |

This webinar, led by the task force co-chairs, will focus on why a joint HTAi-ISPOR Task Force was formed to develop guidance, they will present the minimum set of considerations on the use of deliberative processes in HTA (checklist), and the approach used. During the webinar, participants will have the opportunity to discuss what efforts could be made to ensure the appropriate use and uptake of the guidance, potential gaps and what more might be needed.

A Journey without a Map: Building an Oncology Powerhouse Where Innovation Thrives

September 19th, 2022|Categories: , |Tags: , |

What does it take to deliver the next generation of cancer therapies? And how to stay ahead in a field that’s constantly evolving? These are the questions Astellas’ leaders have been answering during their decade-long journey to build an oncology powerhouse from the ground up. Today, oncology is the company’s largest therapy area of strategic focus and investment and the lessons learned are changing the face of innovation in oncology and beyond.

New Insights into ATMP Valuation and Outcomes-Based Pricing Experience

September 16th, 2022|Categories: |Tags: |

Join us for the Signal event on September 27, 2022 to learn about the Danish experience with ATMP valuation approach and development of an innovative outcomes-based pricing agreement between pharma and payers. You will gain insight into the practicalities of stakeholder involvement and data requirements, and overall learnings from the outcomes-based pricing agreement experience from a multistakeholder perspective.

US Drug Pricing Reform: Potential impact on Pharma HEOR evidence generation

September 7th, 2022|Categories: |Tags: |

On Aug 7th, 2022, the US House of representatives passed a bill on budget reconciliation which included a section on US Drug pricing reform (Part B). The reform requires federal government to negotiate drug prices under Medicare to ensure significant discounts on branded therapies and eliminate annual price increases. The bill further requires pharmaceutical companies to pay rebates if drug prices rise faster than inflation for Medicare and private insurances. Join experts Anna Forsythe, Vice President Value & Access at Cytel, and Dr. Edmund Pezalla, Founder & CEO of Enlightenment Bioconsult, as they discuss the impact of this reform on pricing of new and established therapies and the potential role of health economic evidence to justify product value in future negotiations with CMS.

Evidence Matters 2022

August 31st, 2022|Categories: |Tags: |

Evidence Matters is a virtual one-day summit that brings the literature review community together from different industries to learn, engage, and solve ever-pressing evidence-based research challenges.

Overcoming Patient Recruitment Challenges in Rare Disease Trials – September 28th

August 28th, 2022|Categories: |Tags: |

Rare diseases are thought to affect up to 446 million people worldwide. With more than 7,000 rare diseases, most of which are genetic, it’s vital all patients can access new and effective treatments. We know patient recruitment can be challenging even for non-complex trials, but this issue is exacerbated for rare disease studies due to the much smaller patient populations involved. This can lead to lengthy delays in bringing what can be cutting-edge and potentially life-changing therapies to market.

When the Barrier to a Breakthrough Drug is You Can’t Make It – September 28th

August 28th, 2022|Categories: |Tags: |

Despite all of their promise, newer medicines, especially those based on advanced technologies, have been met with unprecedented challenges in scaling up manufacturing, quality control and commercial launch. Hear how developers have approached different aspects of the manufacturing process to bring new and innovative treatments to patients.

US Drug Pricing Reform: Potential impact on Pharma HEOR Evidence Generation – September 8th

August 28th, 2022|Categories: |Tags: |

On Aug 7th, 2022, the US House of representatives passed a bill on budget reconciliation which included a section on US Drug pricing reform (Part B). The reform requires federal government to negotiate drug prices under Medicare to ensure significant discounts on branded therapies and eliminate annual price increases. The bill further requires pharmaceutical companies to pay rebates if drug prices rise faster than inflation for Medicare and private insurances.

Go to Top